http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 07:01:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy for patients with advanced pancreatic cancer.</p> <p>The advancement follows findings from the company's ongoing Phase 2a study of Namodenoson in patients with advanced pancreatic adenocarcinoma who progressed after at least one prior therapy. The Phase 2a study showed a safety profile and clinical activity, with treatment duration extending beyond 16 months in some patients, stable disease observed in more than 30% of evaluable patients, and 35% of patients remaining on therapy.</p> <p>The Phase 2b study will evaluate http://www.streetinsider.com/FDA/Can-Fite+advances+pancreatic+cancer+drug+to+phase+2b+trial/26481410.html Wed, 13 May 2026 07:00:23 -0400 A.06822034 A.07062511 CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/Press+Releases/Following+Positive+Phase+2a+Pancreatic+Cancer+Data%2C+Can-Fite+Advances+Namodenoson+into+Phase+2b+Combination+Study+with+Immunotherapy/26481372.html <p align="center"><i>Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies</i></p> <p align="justify">Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer.</p> <p align="justify">The planned Phase 2b study follows encouraging findings from the Company’s http://www.streetinsider.com/Press+Releases/Following+Positive+Phase+2a+Pancreatic+Cancer+Data%2C+Can-Fite+Advances+Namodenoson+into+Phase+2b+Combination+Study+with+Immunotherapy/26481372.html Wed, 13 May 2026 07:00:00 -0400 A.06822034 A.07062511 CANF CANF CFBI O.05892622 O.10201402 O.20026344 http://www.streetinsider.com/Press+Releases/Following+Positive+Phase+2a+Pancreatic+Cancer+Data%2C+Can-Fite+Advances+Namodenoson+into+Phase+2b+Combination+Study+with+Immunotherapy/26481372.html <p align="center"><i>Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies</i></p> <p align="justify">Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF; TASE: CANF), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer.</p> <p align="justify">The planned Phase 2b study follows encouraging findings from the Company’s http://www.streetinsider.com/Press+Releases/Following+Positive+Phase+2a+Pancreatic+Cancer+Data%2C+Can-Fite+Advances+Namodenoson+into+Phase+2b+Combination+Study+with+Immunotherapy/26481372.html Wed, 13 May 2026 07:00:00 -0400 A.06822034 A.07062511 CANF CANF CFBI O.05892622 O.10201402 O.20026344